Nova Southeastern University’s Rumbaugh-Goodwin Institute for Cancer Research
RGI’s main goal is to develop newer cancer therapies that can specifically target tumors, with minimal cellular damage and toxicity to the patient. Together with its industrial, academic, and governmental partners, RGI and its researchers are investigating why cancer resists chemotherapy, how resistance can be overcome, which chemotherapeutic agents most likely will work in an individual, and what causes cancer to spread. Long relationships with the National Cancer Institute (NCI) and National Institutes of Health, and the unwavering support of organizations like the Royal Dames of Cancer Research, Inc. support promising therapies.
RGI is steadily advancing research projects toward discovering additional treatments for breast, ovarian, prostate, colorectal, and lung cancers using complementary medicine.
One major innovation of the RGI is “JFD,” a small organic molecule that is anti-angiogenic, meaning it “starves” tumors and other cancer cells by preventing blood flow that supplies the tumors with oxygen and nutrients that would otherwise help them to grow and survive. This molecule is less expensive to manufacture, stable in storage, expected to be less toxic, and is more effective against solid tumors. It is specifically designed to battle breast, ovarian, prostate, lung and colorectal cancers. JFD was discovered in collaboration with the Lombardi Cancer Center of Georgetown University. It is patented in both the United States (U.S. patent 7,875,603 B2) and Japan (Japanese patent 5436544 B).
In addition to the aforementioned patents for discovering JFD, researchers from RGI hold a U.S. patent for discovering a molecule called “F16” (U.S. patent 7,939,557 B2) that is more potent and is specifically designed to combat breast cancer cells.
The Royal Dames of Cancer Research, Inc. is proud to be part of the exciting and productive partnership of NSU and RGI. Through our collective efforts, scientific projects will continue to foster ground–breaking success in keeping cancer survival on the rise.
RGI will soon have a new home inside Nova Southeastern University’s Center for Collaborative Research (CCR). The 215,000 sq.-ft.-facility, under construction by the ANF Group, Inc., is expected to be completed in 2016. Additionally, the CCR will house an IBM supercomputer, one of Florida’s largest wet labs, the NSU Technology Incubator and some of the world’s most accomplished researchers.
NSU is classified as a research university with “high research activity” by the Carnegie Foundation for the Advancement of Teaching. More than 200 research projects are currently underway at NSU, including studies on cardiovascular disease, anti-cancer therapies, chronic fatigue syndrome, autism, coral reef restoration, stem cells and wildlife DNA forensics, among other subjects.
NSU’s Rumbaugh-Goodwin Institute for Cancer Research is led by Executive DirectorAppu Rathinavelu, Ph.D.
Rathinavelu holds several patents, has published more than 40 peer-reviewed research articles, served on the editorial board of several scientific journals and committees, co-authored a text book and given more than 75 presentations at national and international conferences.
Rathinavelu received his Ph.D. in biochemistry from the University of Madras in India and conducted his postdoctoral training at Purdue University in West Lafayette, Ind. In 1992, he joined the Department of Pharmaceutical Sciences at Southeastern University’s College of Pharmacy, which merged with Nova to become Nova Southeastern University in 1994. He also serves as associate dean for institutional planning and development at Nova Southeastern University’s College of Pharmacy.
Photo-Appu Rathinavelu, Ph.D.,executive director of NSU’s Rumbaugh-Goodwin Institute for Cancer Research and associate dean for institutional planning and development at Nova Southeastern University’s College of Pharmacy
UPDATE FROM THE RUMBAUGH GOODWIN INSTITUTE FOR CANCER RESEARCH
With the unwavering support from the Royal Dames, RGI is holding the distinction of being the only Research Institute at NSU with 5 patents for a single invention. All the five patents are for the discovery of new cancer therapeutics that was code named as JFD in 2010. Taking this new drug to patient's bedside anywhere in the world would be one of RGI's missions for the near future. RGI is working very closely with Dr. Thomas Temple to find targeted therapies for treating children with sarcomas (bone cancers). As part of this initiative an oncogene called MDM2, which Dr. Rathinavelu's team has researched for nearly 15 years, is being evaluated at RGI as an effective target for safer treatment of bone cancers in children under the new initiative named 'Translating Discovery to Cure Children with Cancer'.
NIH (National Institute of Health) funded Scientist has joined RGI
Dr. Itriy Minond, Ph. D. who was an Associate Professor at Auburn University has joined RGI from June 19, 2017. This new scientist has many years of research experience and funding from NIH and, he will be collaborating with the Scripps Research Institute of Florida and other institutions for discovering new drugs to treat melanoma.
Applications and Funding: RGI has submitted three grant proposals from the beginning of 2017, including the last proposal that was submitted to NCI seeking funds to support research related to the development of new immunotherapeutics.
RGI is in the process of establishing collaborations with the H2Bio of Fort Lauderdale, Florida. As part of this new collaboration, RGI will be offering its expertise towards performing the pre-clinical testing of their new therapeutic drug that is being tested for treating lung cancers.
Watch the first episode or TRED Talks, a video series brought to you by Nova Southeastern University Translational Research and Economic Development (TRED)
Finding Better Treatment Options Medical progress in the fight against cancer is happening, but never fast enough. Please take a moment to hear about how NSU researchers are rapidly developing new and safer cancer therapies.
For more information, contact H. Thomas Temple, M.D.
Senior VP for Translational Research and Economic Development
call (954) 262-7603 or email email@example.com